Quantcast

Latest regorafenib Stories

2009-09-22 02:05:00

BERLIN, Sept. 22 /PRNewswire/ -- Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society...

2009-09-17 01:31:00

BERLIN, Sept. 17 /PRNewswire/ -- Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany. "Bayer is committed to discovering and...

2009-05-22 05:00:00

WAYNE, N.J., May 22 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced that new data on Bayer's novel anti-cancer development candidate BAY 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2. "Bayer is committed to expanding our oncology franchise, and the oral multi-kinase inhibitor BAY 73-4506 is one of the promising compounds in the company's pipeline," said...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.